Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2008

Conditions
HIV InfectionsHepatitis C
Interventions
DRUG

Peginterferon alfa-2a + ribavirin

Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks

Trial Locations (19)

11009

Hospital Puerta del Mar, Cadiz

11407

Hospital de Jerez, Jerez de la Frontera

15705

Complejo Hospitalario Universitario, Santiago

18013

Hospital Clínico Universitario San Cecilio, Granada

20014

Hospital de Donostia, San Sebastián

28040

Hospital Clínico San Carlos, Madrid

28041

Hospital 12 de Octubre, Madrid

28046

Hospital La Paz, Madrid

28922

Fundación Hospital de Alcorcón, Alcorcón

35016

Hospital Insular, Las Palmas

41008

Hospital Virgen Macarena, Seville

41013

Hospital Virgen del Rocío, Seville

41014

Hospital de Valme, Seville

46014

Consorcio Hospital General, Valencia

47011

Hospital Clínico de Valladolid, Valladolid

01009

Hospital de Txagorritxu, Vitoria-Gasteiz

08025

Hospital Santa Creu i Sant Pau, Barcelona

08907

Hospital de Bellvitge, L'Hospitalet de Llobregat

07014

Hospital Son Dureta, Palma de Mallorca

All Listed Sponsors
lead

Hospital Clinico Universitario San Cecilio

OTHER

NCT00612755 - Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4 | Biotech Hunter | Biotech Hunter